share_log

Chardan Capital Maintains Buy on Better Therapeutics, Lowers Price Target to $14

Chardan Capital Maintains Buy on Better Therapeutics, Lowers Price Target to $14

Chardan Capital维持买入Better Treatetics,将目标价下调至14美元
Benzinga Real-time News ·  2022/11/15 07:06

Chardan Capital analyst Keay Nakae maintains Better Therapeutics (NASDAQ:BTTX) with a Buy and lowers the price target from $17 to $14.

Chardan Capital分析师Keay Nakae维持了Better Treateutics(纳斯达克:BTTX)的买入,并将目标价从17美元下调至14美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发